SAFARI Trial
Cross-source consensus on SAFARI Trial from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Comparisons
Evidence quality
Highlighted claims
- SAFARI was an open-label, randomized, controlled phase 2 trial conducted at two Nigerian Lassa fever referral centers. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- The study compared oral favipiravir with intravenous ribavirin, which was the Nigerian standard of care. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- SAFARI primarily aimed to characterize favipiravir pharmacokinetics and assess its safety and tolerability. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- The trial enrolled 41 participants between August 2021 and October 2022. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- The trial was not blinded because the study drugs differed in formulation and route of administration. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial